Related references
Note: Only part of the references are listed.
Article
Oncology
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
Kendall D. Carey et al.
CANCER RESEARCH (2006)
Article
Oncology
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Review
Oncology
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
LF Allen et al.
SEMINARS IN ONCOLOGY (2002)
Share Paper
